Affimed N.V.

0.00 (-0.24%)
Earnings Announcements

Affimed Reports Q3 2022 Financial Results

Published: 11/15/2022 11:39 GMT
Affimed N.V. (AFMD) - Affimed Reports Third Quarter 2022 Financial Results and Highlights Recent Clinical and Corporate Progress.
Cash and Cash Equivalents As of September 30, 2022, Were Approximately EUR 222.9 Million With Anticipated Cash Runway Into Mid-2024.
Afm28: Clinical Trial Applications (cta) Have Been Filed in European Countries and Initiation of Phase 1 Study is Expected in H1 of 2023.
Afm13 Monotherapy: on Track to Report Topline Data of Registration-directed Redirect Trial in Mid-december 2022.
Net Loss for Quarter Ended September 30, 2022, Was EUR 16.5 Million, Or EUR 0.11 Loss per Common Share.
Q3 Earnings per Share View EUR -0.18 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $6.25 Million
Adjusted EPS is expected to be -$0.20

Next Quarter Revenue Guidance is expected to be $5.28 Million
Next Quarter EPS Guidance is expected to be -$0.18

More details on our Analysts Page.